Iovance Biotherapeutics (IOVA) stock soared 40% after posting Q2 revenue of $99.3M, beating estimates by $11.5M and driving guidance review. The post Iovance Biotherapeutics (IOVA) Stock Rockets Over 40% on Blowout Q2 Earnings appeared first on Blockonomi.